|
1
|
Agid Y: Parkinson’s disease:
pathophysiology. Lancet. 337:1321–1324. 1991.
|
|
2
|
Ono S, Hirai K and Tokuda E: Effects of
pergolide mesilate on metallothionein mRNAs expression in a mouse
model for Parkinson disease. Biol Pharm Bull. 32:1813–1817. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fox SH, Visanji NP, Johnston TH,
Gomez-Ramirez J, Voon V and Brotchie JM: Dopamine receptor agonists
and levodopa and inducing psychosis-like behavior in the MPTP
primate model of Parkinson disease. Arch Neurol. 63:1343–1344.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tayarani-Binazir K, Jackson MJ, Rose S,
McCreary AC and Jenner P: The partial dopamine agonist pardoprunox
(SLV308) administered in combination with l-dopa improves efficacy
and decreases dyskinesia in MPTP treated common marmosets. Exp
Neurol. 226:320–327. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barlow RB and Johnson O: Relations between
structure and nicotine-like activity: X-ray crystal structure
analysis of (−)-cytisine and (−)-lobeline hydrochloride and a
comparison with (−)-nicotine and other nicotine-like compounds. Br
J Pharmacol. 98:799–808. 1989.PubMed/NCBI
|
|
6
|
Dimatelis JJ, Russell VA, Stein DJ and
Daniels WM: The effects of lobeline and naltrexone on
methamphetamine-induced place preference and striatal dopamine and
serotonin levels in adolescent rats with a history of maternal
separation. Metab Brain Dis. 27:351–361. 2012. View Article : Google Scholar
|
|
7
|
Rozas G and Labandeira García JL:
Drug-free evaluation of rat models of parkinsonism and nigral
grafts using a new automated rotarod test. Brain Res. 749:188–199.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Damier P, Hirsch EC, Agid Y and Graybiel
AM: The substantia nigra of the human brain. I Nigrosomes and the
nigral matrix, a compartmental organization based on calbindin
D(28K) immunohistochemistry. Brain. 122:1421–1436. 1999. View Article : Google Scholar
|
|
9
|
Szego ÉM, Gerhardt E, Kermer P and Schulz
JB: A30P α-synuclein impairs dopaminergic fiber regeneration and
interacts with L-DOPA replacement in MPTP-treated mice. Neurobiol
Dis. 45:591–600. 2012.
|
|
10
|
Graham D and Langer SZ: Advances in
sodium-ion coupled biogenic amine transporters. Life Sci.
51:631–645. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McChargue DE, Collins FL Jr and Cohen LM:
Effect of non-nicotinic moist snuff replacement and lobeline on
withdrawal symptoms during 48-h smokeless tobacco deprivation.
Nicotine Tob Res. 4:195–200. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu R, Guo X, Park Y, Huang X, Sinha R,
Freedman ND, Hollenbeck AR, Blair A and Chen H: Caffeine intake,
smoking, and risk of Parkinson disease in men and women. Am J
Epidemiol. 175:1200–1207. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen H, Huang X, Guo X, Mailman RB, Park
Y, Kamel F, Umbach DM, Xu Q, Hollenbeck A, Schatzkin A and Blair A:
Smoking duration, intensity, and risk of Parkinson disease.
Neurology. 74:878–884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sieber M: Neuroprotective properties of
nicotine. Curr Med Chem. 19:292–297. 2012. View Article : Google Scholar
|
|
15
|
Singh K, Singh S, Singhal NK, Sharma A,
Parmar D and Singh MP: Nicotine- and caffeine-mediated changes in
gene expression patterns of MPTP-lesioned mouse striatum:
Implications in neuroprotection mechanism. Chem Biol Interact.
185:81–93. 2010. View Article : Google Scholar
|
|
16
|
Li Y, Yu DQ, Peng Y, Feng YH, Zhang DM,
Zhao J, Zhang WQ and Sun YP: The protective effect of nicotine on
dopaminergic neuron of Parkinson’s disease mice. Zhongguo Ying Yong
Sheng Li Xue Za Zhi. 23:425–429. 2007.(In Chinese).
|
|
17
|
Parain K, Hapdey C, Rousselet E, Marchand
V, Dumery B and Hirsch EC: Cigarette smoke and nicotine protect
dopaminergic neurons against the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin.
Brain Res. 984:224–232. 2003. View Article : Google Scholar
|
|
18
|
Harrod SB, Lacy RT, Zhu J, Hughes BA,
Perna MK and Brown RW: Gestational IV nicotine produces elevated
brain-derived neurotrophic factor in the mesocorticolimbic dopamine
system of adolescent rat offspring. Synapse. 65:1382–1392. 2011.
View Article : Google Scholar
|
|
19
|
Toulorge D, Guerreiro S, Hild A, Maskos U,
Hirsch EC and Michel PP: Neuroprotection of midbrain dopamine
neurons by nicotine is gated by cytoplasmic Ca2+. FASEB
J. 25:2563–2573. 2011. View Article : Google Scholar : PubMed/NCBI
|
